Medical Supplies

Pre-filled Syringes Market 2020-2024- Baxter International Inc., Becton, Dickinson and Co., Recipharm AB, among others to contribute to the market growth|Industry Analysis, Market Trends, Opportunities and Forecast 2024 | Technavio

Thursday, January 21, 2021 - 7:50pm

The pre-filled syringes market is poised to grow by $ 4.23 bn during 2020-2024, decelerating at a CAGR of almost 13% during the forecast period.

Key Points: 
  • The pre-filled syringes market is poised to grow by $ 4.23 bn during 2020-2024, decelerating at a CAGR of almost 13% during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20210121005865/en/
    Technavio has announced its latest market research report titled Global Pre-filled Syringes Market 2020-2024 (Graphic: Business Wire)
    Worried about the impact of COVID-19 on your Business?
  • The report on the pre-filled syringes market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • This study identifies the increasing number of biopharmaceuticals as one of the prime reasons driving the pre-filled syringes market growth during the next few years.

The Vistria Group and Excellere Partners Invest in SCA Pharmaceuticals

Thursday, January 21, 2021 - 4:59pm

The Vistria Group and Excellere Partners have purchased all of the issued and outstanding equity interests of SCA Pharma.

Key Points: 
  • The Vistria Group and Excellere Partners have purchased all of the issued and outstanding equity interests of SCA Pharma.
  • We are very pleased that as we continue our expansion efforts and improvements in our efficiencies, our new partnership with The Vistria Group and Excellere will allow us to accelerate these efforts, said Milton Boyer, CEO of SCA Pharma.
  • We look forward to working with Excellere to take the high standards set by SCA even further, said Jon Maschmeyer, Partner at Vistria.
  • An emerging national leader in compounded pharmaceuticals, SCA Pharma previously was wholly owned by Enhanced Healthcare Partners.

Hemolung® RAS Used to Treat More than 75 COVID-19 Patients

Thursday, January 21, 2021 - 2:05pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210121005186/en/
    The Hemolung RAS has enabled us to recover patients with COVID pneumonia during the pandemic.
  • The Hemolung RAS has given us a new tool during the current pandemic, to safely and easily treat our COVID-19 patients.
  • We were able to rapidly introduce the Hemolung RAS to our staff and start treating patients under Emergency Use Authorization.
  • For more information on the use of the Hemolung RAS for COVID-19 patients, please visit https://www.alung.com/covid-19/covid-19-us/
    *The Hemolung RAS has not been FDA cleared or approved.

RapidAI Enhancing Stroke Care Across Australia

Thursday, January 21, 2021 - 2:00pm

RapidAI, the leader in advanced imaging for stroke, today announced it now serves over 50 hospitals and teleradiology services in Australia.

Key Points: 
  • RapidAI, the leader in advanced imaging for stroke, today announced it now serves over 50 hospitals and teleradiology services in Australia.
  • Australia is a vast country and I am delighted to see more people having access to faster care irrespective of their postcode.
  • RapidAI makes the most-widely used advanced cerebrovascular imaging products for patient care, research, and clinical trials across the globe.
  • RapidAI clinical products help save lives, RapidAI workflow and messaging technologies help stroke teams save time, and RapidAI analytics and business intelligence products help stroke networks reduce costs and improve patient outcomes.

Bluma Wellness Inc. Provides End-of-Month Operations Update and Financial Highlights for December 2020

Thursday, January 21, 2021 - 1:35pm

Bluma Wellness Inc. (the Company or Bluma Wellness) (CSE: BWEL.U) is pleased to provide its patients and investors with an end-of-month sales and operations report for the month ended December 31, 2020.

Key Points: 
  • Bluma Wellness Inc. (the Company or Bluma Wellness) (CSE: BWEL.U) is pleased to provide its patients and investors with an end-of-month sales and operations report for the month ended December 31, 2020.
  • The financial highlights disclosed in this press release are management prepared and have not been audited or reviewed by the Companys auditors.
  • Bluma Wellness is pleased to provide the following sales and financial highlights from the month of December 2020:
    Revenues less cost of sales before fair value adjustments: approx.
  • 2 Gross Price per Pound is calculated as total revenue divided by total pounds of dried medical cannabis flower sold.

HealthTrust to Co-Manage New Manufacturing Business for Domestic Production of Surgical and Procedure Masks

Thursday, January 21, 2021 - 1:46pm

HealthTrust , a global leader in purchasing aggregation and performance improvement for healthcare, announced today that it will co-manage operations of a newly formed company created to manufacture surgical and procedure masks in the United States.

Key Points: 
  • HealthTrust , a global leader in purchasing aggregation and performance improvement for healthcare, announced today that it will co-manage operations of a newly formed company created to manufacture surgical and procedure masks in the United States.
  • Domestic production of Level 1 and Level 3 masks meeting American Society for Testing and Materials (ASTM) standards for quality and safety is expected to begin in early 2021 from a manufacturing center in Asheville, N.C.
  • Exclusive distribution will be through a controlled channel managed by HealthTrust subsidiary Resource Optimization & Innovation (ROi), giving the operator total visibility of the supply chain from raw materials to finished goods.
  • Resource Optimization & Innovation, LLC (ROi), a subsidiary of HealthTrust, is a St. Louis-based group purchasing organization.

HCA Healthcare Invests in Domestic Production of PPE

Thursday, January 21, 2021 - 1:30pm

Investment in the new business entity will initially be funded equally by HCA Healthcare Mission Fund, LLC, an affiliate of HCA Healthcare, and A Plus.

Key Points: 
  • Investment in the new business entity will initially be funded equally by HCA Healthcare Mission Fund, LLC, an affiliate of HCA Healthcare, and A Plus.
  • The new business entity is part of HCA Healthcares continued effort to support healthcare workers and address the global demand for PPE.
  • HCA Healthcares investment in the business is being funded through the HCA Healthcare Mission Fund , an innovation fund created following HCA Healthcares purchase of Mission Health to support healthcare-related businesses in Western North Carolina.
  • All references to Company, HCA and HCA Healthcare as used throughout this document refer to HCA Healthcare, Inc. and its affiliates.

HempFusion Announces Large-Scale Distribution Agreement with Fullscript.com to Launch Doctor Practitioner Sales Channel

Thursday, January 21, 2021 - 12:01pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210121005282/en/
    Total Care Daily Probiotic from Biome Research (Photo: Business Wire)
    This agreement signifies HempFusions strategic launch into the doctor practitioner sales channel.
  • We are incredibly excited to launch doctor practitioner sales starting with Biome Research, a specialized wholly-owned HempFusion brand designed specifically for doctors, practitioners and their patients, stated Nancy Angelini, HempFusions Director of Doctor/Practitioner.
  • An industry-leading eCommerce platform like Fullscript, with a deep and established distribution network, is a tremendous advantage to HempFusion.
  • The launch into the doctor practitioner sales channel is crucial.

QIAGEN Plans to Resubmit EUA Submission in the U.S. for QIAreach SARS-CoV-2 Antigen Test in the First Quarter of 2021

Wednesday, January 20, 2021 - 9:08pm

This comes after QIAGEN decided to proactively withdraw the first submission made in November 2020 for this product to address a chemistry-related issue.

Key Points: 
  • This comes after QIAGEN decided to proactively withdraw the first submission made in November 2020 for this product to address a chemistry-related issue.
  • QIAGEN believes it has resolved the issue, and data is now being collected for submission to the FDA.
  • QIAGEN launched the QIAreach SARS-CoV-2 Antigen test in November 2020.
  • QIAGEN does not expect this decision to have an impact on the outlook for full-year 2021 sales and adjusted earnings, as communicated in December 2020.

ParcelShield Expands Executive Team with New CPTO, CCO

Wednesday, January 20, 2021 - 7:03pm

ParcelShield , a technology and data analytics company committed to transforming logistics and parcel management for healthcare, today announced that two new hires have joined the companys executive team.

Key Points: 
  • ParcelShield , a technology and data analytics company committed to transforming logistics and parcel management for healthcare, today announced that two new hires have joined the companys executive team.
  • They are Neil Garnichaud, who will serve as Chief Product & Technology Officer, and Scott Helfrich, who will be the new Chief Commercial Officer.
  • Its not every day that two top-tier executives, each with deep experience in technology, sales and marketing in the healthcare industry, join our executive team!
  • We could not be happier to welcome Scott and Neil aboard as we work to revolutionize how healthcare is delivered.